propafenone
DISEASE INTERVENTION COMPARISON RESULTS
Am Heart J. 2008 Jan;155(1):100-7, 107.e1 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal, persistent, StudyID: PITAGORA 2008 The Use of
flecainide, or propafenone
As Treatment, Chronic
Is equal Than
amiodarone, sotalol
To modify, at 2 years, AF recurrence, mortality, adverse events
N Engl J Med. 2004 Dec 2;351(23):2384-91 Clinical Trial (non-controlled, non-randomized)
IN atrial fibrillation, paroxysmal, recurrent, mild or no cardiopathy The Use of
pill-in-the-pocket approach: self-administered oral loading of flecainide or propafenone
As Treatment, Chronic
Is useful Than
historical comparison
To reduce presumed AF recurrences, at 1.5 years (treatment successful in 84% of palpitations episodes), reducing emergency deparment visits, with 7% adverse events (1.5% severe)
J Am Coll Cardiol. 1988 Oct;12(4):1005-11 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Antman 1990 (subordinated publication), atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 6 months
J Am Coll Cardiol. 1990 Mar 1;15(3):698-707 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Antman 1990, atrial fibrillation The Use of
propafenone, sotalol if failure, sequentially
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 6 months
Deutsche Medizinische Wochenschrift. 1978 Jun 30;103(26):1068-72 Randomized Controlled Trial
IN StudyID: Beck 1978, atrial fibrillation, persistent The Use of
propafenone
As Treatment, Acute
Is equal Than
lidoflazine
To acute conversion of AF
Curr Ther Res Clin Exp. 1995;56(11):1154-1168 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Cardiology Review 2002;19(9):18-21 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
G Ital Cardiol. 1996 Apr;26(4):379-90 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Munchener Medizinische Wochenschrift. 1996;138 (12):39-46 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Am J Cardiol. 2001 Sep 15;88(6):640-5 Randomized Controlled Trial
IN StudyID: Bellandi 2001, atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Am J Cardiol. 1989 Apr 1;63(12):817-9 Cross-Over
IN StudyID: Connolly 1989, atrial fibrillation, paroxysmal, recurrent The Use of
propafenone
As Treatment, Chronic
Is equal Than
placebo
To AF symptomatic recurrence
Acta Cardiol. 2004 Jun;59(3):255-61 Randomized Controlled Trial
IN StudyID: Dogan 2004, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To at 15 months: AF recurrence, adverse effects
Am J Cardiol. 2002 Dec 15;90(12):1300-6 Randomized Controlled Trial, Multicenter Trial
IN StudyID: ERAFT 2002, atrial fibrillation, paroxysmal The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse events - at what time?
Am J Cardiol. 1988 Feb 15;61(6):473-4 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Hammil 1988, atrial fibrillation, persistent The Use of
propafenone
As unknow
Is - Than
unknow
To unknow
Am J Cardiol. 1988 Apr 15;61(11):914-6 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Kerr 1988, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is - Than
not available
To not available
Chest. 2004 Feb;125(2):377-83 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmPro 2004, atrial fibrillation The Use of
amiodarone, propafenone
As Treatment, Chronic
Is good Than
0
To AF recurrence, adverse effects - at 10 months
Pacing Clin Electrophysiol. 2000 Nov;23(11 Pt 2):1883-7 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmSot 2000 (subordinated publication), atrial fibrillation The Use of
amiodarone, propafenone
As Treatment, Chronic
Is better Than
sotalol
To AF recurrence, adverse effects - at 6 to 16 months
Am J Cardiol. 2004 Dec 15;94(12):1563-6 Randomized Controlled Trial
IN StudyID: Kochiadakis-ProSot 2004, atrial fibrillation The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To mortality, pro-arrhythmia, AF recurrence, adverse effects - at 18 to 25 months
Can J Cardiol. 1991 Nov;7(9):407-9 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Kyles 1991, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 30 months
Arch Mal Coeur Vaiss. 2002 Jun;95(6):567-72 Clinical Trial (non-controlled, non-randomized)
IN StudyID: PEPS 2002, atrial fibrillation, rejected The Use of
propafenone
As Treatment, Chronic
Is useful Than
not controlled
To AF recurrence, adverse effects, pro-arrhythmia - at 12 months
Am J Cardiol. 1989 Jan 1;63(1):114-6 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Porterfield 1989, atrial fibrillation, persistent The Use of
propafenone
As unknow
Is - Than
unknow
To unknow
Cardiovasc Drugs Ther. 1996 May;10(2):145-52 Randomized Controlled Trial
IN StudyID: PRODIS 1996, atrial fibrillation, persistent The Use of
propafenone
As Treatment, Chronic
Is better Than
disopyramide
To mortality, AFrecurrence, adverse effects, pro-arrhythmia - at 6 months
Circulation. 1995 Nov 1;92(9):2550-7 Randomized Controlled Trial
IN StudyID: PSVT 1995, atrial fibrillation, rejected The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at ? Time
Am J Cardiol. 2003 Oct 15;92(8):941-6 Randomized Controlled Trial
IN StudyID: RAFT 2003, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at ? Time
Am J Cardiol. 1993 Mar 1;71(7):558-63 Randomized Controlled Trial
IN StudyID: Reimold 1993, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is equal Than
sotalol
To AF recurrence, adverse effects, mortality - at 12 months
Cardiologia. 1992 Feb;37(2):123-7 Randomized Controlled Trial
IN StudyID: Richiardi 1992, atrial fibrillation, paroxysmal The Use of
propafenone
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrence, adverse effects - at 6 months
Prog Cardiovasc Dis. 2001 Sep-Oct;44(2):121-52 Meta-Analysis
IN StudyID: Slavik 2001, atrial fibrillation The Use of
IV procainamide, oral quinidine, oral flecainide, oral propafenone, IV or hight-dose oral amiodarone, IV ibutilide
As Treatment, Acute
Is better Than
placebo
To converting AF to sinus rhythm
Am J Cardiol. 1997 Feb 15;79(4):418-23 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Stroobandt 1997, atrial fibrillation, persistent The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 months